The difference often lies in the GLP-1 response
Retatrutide Side Effects The Phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) reported gastrointestinal adverse events as the dominant side-effect pattern, consistent with other GLP-1-class drugs
Chi YQ, Yao Y, Zhang WH, Zhang ZH, Wang YH, Hao W (2025) Docosahexaenoic acid supplementation for neonatal hyperbilirubinemia: a double-blind, randomized clinical trial
However, alongside their clinical benefits, a rapidly expanding legal landscape has emerged, centering on product liability claims and multidistrict litigation against drugmakers over alleged serious side effects and inadequate safety warnings
Gastrointestinal symptoms : Persistent nausea, vomiting, or diarrhoea can lead to dehydration, electrolyte imbalances, and reduced nutrient absorption, all contributing to tiredness